- Home
- / OLYMVAX
OLYMVAX
Stock Price
¥10.8
2024-10-29
Market Capitalization
¥4.2 B
2024-10-29
Revenue
¥694.1 M
FY, 2025
OLYMVAX Summary
Company Summary
- Overview
- Chengdu Olymvax Biopharmaceuticals (成都欧林生物科技股份有限公司) is a biopharmaceutical company that produces and sells vaccines. It offers tetanus, haemophilus influenzae, meningococcal conjugate, and other vaccines.
- Type
- Public
- Status
- Active
- Founded
- 2009
- HQ
- Chengdu, CN | view all locations
- Website
- http://en.olymvax.com/
- Cybersecurity rating
Table of Contents
Key People
Tan Yong, Chief Financial Officer
Ma Hengjun, Executive Vice General Manager
Wu Wei, Secretary of the Board
LocationsView all
3 locations detected
Chengdu, Si Chuan Sheng HQ
China
No. 99 Tianxin Road, Hi-Tech Zone (West)
Chengdu, Sichuan
China
No. 18, Section 2, Biocity Middle Road, Shuangliu District
Chongqing, Chongqing
China
No. 15, Building 2-1, Phase II, Qingfeng Hi-Tech Innovation Incubation Center Project
OLYMVAX Financials
Summary Financials
- Revenue (Q1, 2026)
- ¥155.2M
- Gross profit (Q1, 2026)
- ¥142.3M
- Net income (Q1, 2026)
- ¥27.2M
- Cash (Q1, 2026)
- ¥192.3M
- EBIT (Q1, 2026)
- ¥36.5M
- Enterprise value
- $4.5B